First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
Advanced Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 56 (final count)
- Started
- Oct 29, 2020
- Main results expected
- Dec 28, 2023
- Fully finished
- Dec 28, 2023
- Results posted
- Jan 15, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Measured over: Up to approximately 3 years
Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0)
Measured over: Cycle 1 (21 days for Schedule A and 28 days for Schedule B)
Dose Expansion Phase: Objective Response Rate (ORR) - Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Measured over: Up to approximately 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04622774 · record last updated 2025-01-15 · checked 2026-11-09 15:47 UTC